MediWound (MDWD) will host a virtual Key Opinion Leader event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE study in venous leg ulcers and EscharEx’s commercial opportunity. Discussion Topics Include: Compelling results to date from Phase II studies of EscharEx The upcoming Phase III VALUE study of EscharEx in VLUs The substantial unmet need and current treatment landscape for VLUs and diabetic foot ulcers EscharEx’s competitive advantages and unique commercial potential
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD:
- MediWound Executives Acquire 18,462 Shares, Signaling Confidence in Company’s Future
- MediWound price target lowered to $25 from $28 at H.C. Wainwright
- MediWound Advances Enzymatic Therapeutics Amid Financial Shifts
- MediWound Advances with FDA Approval and New Funding
- MediWound reports Q3 EPS (98c), consensus (44c)